This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Ofatumumab, HuMax-CD20, GSK1841157, OMB157
BioMedTracker has separate profiles for the autoimmune and oncology indications of Arzerra to account for the GlaxoSmithKline / Novartis licensing deals. Please also see our Arzerra (Autoimmune) drug profile.
Arzerra is a fully human, high-affinity antibody targeted at the CD20 molecule in the cell membrane of B-cells. In certain types of cancer, these cells can proliferate too much and treatment is needed to reduce the number of B-cells.
All historical revenues for Arzerra are recorded under the oncology profile.
GlaxoSmithKline and Genmab
In December 2006, GlaxoSmithKline and Genmab announced a worldwide agreement to co-develop and commercialize Arzerra. Under the terms of the agreement, Genmab will receive a license fee of DKK 582 million (approximately 52 million and approximately $102 million), and GSK will invest DKK 2033 million (approximately 183 million and approximately $357 million) to purchase, 4,471,202 ordinary shares of Genmab. The total potential value of this agreement, in the event of full commercial success,in cancer and various autoimmune and inflammatory diseases, could exceed DKK 12.0 billion (approximately 1.1 billion and approximately $2.1 billion), including the initial license fee and equity purchase, milestone payments, totaling DKK 9.0 billion (approximately 0.8 billion and approximately $1.6 billion) and expected development, commercial manufacturing and...See full deal structure in Biomedtracker
Partners: Genmab A/S DRI Capital Inc.
Arzerra (Oncology) News
Additional information available to subscribers only: